Krystal Biotech, Inc.

Equities

KRYS

US5011471027

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-18 pm EDT 5-day change 1st Jan Change
168.5 USD -2.57% Intraday chart for Krystal Biotech, Inc. -1.09% +35.85%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Krystal Biotech Insider Sold Shares Worth $8,547,719, According to a Recent SEC Filing MT
Krystal Biotech Insider Sold Shares Worth $8,547,719, According to a Recent SEC Filing MT
Sector Update: Health Care Stocks Ease Late Afternoon MT
Sector Update: Health Care Stocks Weaker Monday Afternoon MT
Top Midday Gainers MT
Krystal Biotech Shares Jump After Surprise Q4 Profit MT
Krystal Biotech Swings to Q4 Profit as Company Generates Revenue; Shares Climb Pre-Bell MT
Transcript : Krystal Biotech, Inc., Q4 2023 Earnings Call, Feb 26, 2024
Krystal Biotech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (KRYS) KRYSTAL BIOTECH Posts Q4 EPS $0.30, vs. Street Est of $-0.25 MT
Krystal Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Traders Await Inflation Data This Week DJ
MORNING BID AMERICAS-Booming stocks step back as PCE hoves into view RE
Krystal Biotech Says FDA Grants Fast Track Designation to Inhaled KB707 for Lung Tumors Treatment MT
Krystal Biotech Secures J-code for Vyjuvek MT
Krystal Biotech Receives Permanent J-Code for VYJUVEK® CI
Krystal Biotech Says Japan Grants Orphan Drug Designation to Skin Disease Treatment; Shares Rise Pre-Bell MT
Krystal Biotech Insider Sold Shares Worth $5,283,291, According to a Recent SEC Filing MT
Krystal Biotech Insider Sold Shares Worth $5,283,291, According to a Recent SEC Filing MT
Krystal Biotech Says European Regulator Validates Marketing Authorization Application for Skin Disease Treatment MT
Krystal Biotech Announces EMA Validation of Marketing Authorization Application for Vyjuvek for the Treatment of Dystrophic Epidermolysis Bullosa CI
Sector Update: Health Care Stocks Advance Premarket Monday MT
Transcript : Krystal Biotech, Inc., Q3 2023 Earnings Call, Nov 06, 2023
Krystal Biotech Swings to Profit in Q3; Generates Revenue MT
Krystal Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Chart Krystal Biotech, Inc.
More charts
Krystal Biotech, Inc. is a biotechnology company. The Company is focused on the development of redosable gene therapies for patients living with debilitating diseases. It has developed a gene delivery platform that enables off-the-shelf treatments for serious dermatology and respiratory diseases. Its platform consists of an engineered viral vector derived from the herpes simplex virus type 1 (HSV-1) that it has optimized for local and repeat gene transfer to epithelial cells. Its product candidates in various stages of clinical and preclinical development include Vyjuvek for dystrophic epidermolysis bullosa (Dystrophic EB), KB105 for TGM1-deficient autosomal recessive congenital ichthyosis (ARCI), KB104 for Netherton Syndrome, KB407 for Cystic Fibrosis (CF), and KB408 for Alpha-1 antitrypsin deficiency (AATD). Its KB301 is for aesthetic skin conditions. The Company's subsidiary, Jeune Aesthetics, Inc., which focuses on preclinical and clinical studies for aesthetic skin conditions.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
168.5 USD
Average target price
185.9 USD
Spread / Average Target
+10.31%
Consensus
  1. Stock
  2. Equities
  3. Stock Krystal Biotech, Inc. - Nasdaq
  4. News Krystal Biotech, Inc.
  5. Krystal Biotech : GeneDx to Offer Free Genetic Testing for Dystrophic Epidermolysis Bullosa